© NL Communications, Inc. 2001. All rights reserved. This program was supported by an unrestricted educational grant from AstraZeneca Pharmaceuticals LP. The audio tapes, compact discs, Internet content and accompanying printed material is protected by copyright. No part of this program may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or utilizing any information storage and retrieval system, without written permission from the copyright owner. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor. As part of this program, materials and presentations may include information regarding the use of drugs that may be inconsistent with or outside the approved labeling of these products. Healthcare professionals should note that the use of these agents outside current approved labeling is considered experimental and are advised to consult prescribing information for these products. Please refer to the U.S. product information for complete information about each drug.

Home

Editor’s Note

Neoadjuvant endocrine therapy

Is four cycles of AC adequate adjuvant therapy?

Taxanes in the adjuvant and metastatic setting

Aromatase inhibitors in clinical practice

Combination endocrine therapy

Tamoxifen and quality of life

Long-term survival with metastatic breast cancer

Capecitabine for metastatic disease

Menopause and hormone replacement in breast cancer patients

Pregnancy after breast cancer treatment

Editorial Office